Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
VaccinesInfectious Disease

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1777779

Cover Image

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1777779

Anthrax Vaccine

PUBLISHED:
PAGES: 375 Pages
DELIVERY TIME: 1-2 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
PDF (Single User License)
USD 5850
PDF (Global License to Company and its Fully-owned Subsidiaries)
USD 17550

Add to Cart

Description

Table of Contents

Global Anthrax Vaccine Market to Reach US$15.6 Billion by 2030

The global market for Anthrax Vaccine estimated at US$12.9 Billion in the year 2024, is expected to reach US$15.6 Billion by 2030, growing at a CAGR of 3.2% over the analysis period 2024-2030. Cell-Free PA Vaccines, one of the segments analyzed in the report, is expected to record a 4.0% CAGR and reach US$8.4 Billion by the end of the analysis period. Growth in the Live Cell Vaccines segment is estimated at 2.3% CAGR over the analysis period.

The U.S. Market is Estimated at US$3.5 Billion While China is Forecast to Grow at 6.1% CAGR

The Anthrax Vaccine market in the U.S. is estimated at US$3.5 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$3.1 Billion by the year 2030 trailing a CAGR of 6.1% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.2% and 2.5% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.8% CAGR.

Global Anthrax Vaccine Market - Key Trends & Drivers Summarized

Why Are Anthrax Vaccines Crucial in Public Health and Biodefense?

Anthrax vaccines have emerged as a cornerstone in public health and biodefense strategies due to the severe health and security risks posed by anthrax outbreaks. Caused by Bacillus anthracis, anthrax can lead to life-threatening infections in humans and animals, with the inhalational form of the disease being particularly lethal. Vaccination programs have proven effective in preventing the spread of anthrax, especially in high-risk groups such as military personnel, first responders, and individuals working in agriculture or veterinary fields. The potential use of anthrax as a bioterrorism agent has further underscored the importance of vaccines in biodefense preparedness. Governments worldwide are actively investing in the development, production, and stockpiling of anthrax vaccines to safeguard against intentional outbreaks. Public health campaigns have also focused on raising awareness about the importance of vaccination in at-risk communities, leading to an increase in vaccine coverage and market demand. These factors collectively highlight the critical role of anthrax vaccines in protecting global health and security.

What Advances Are Driving Innovation in Anthrax Vaccine Development?

The anthrax vaccine market has seen significant advancements in vaccine development, with a strong emphasis on improving safety, efficacy, and accessibility. Traditional anthrax vaccines, such as BioThrax (AVA), rely on cell-free filtrates containing protective antigens. While effective, these vaccines often require multiple doses and booster shots, which can limit compliance and scalability. Recent innovations have focused on developing next-generation vaccines that reduce the number of doses, improve immunogenicity, and minimize adverse effects. Recombinant DNA technology has enabled the creation of vaccines that target specific anthrax antigens, enhancing their ability to elicit a robust and long-lasting immune response. Adjuvants, which are substances added to vaccines to boost their effectiveness, have also been incorporated into new formulations to improve potency and reduce dosing schedules. Additionally, researchers are exploring nasal and oral vaccine delivery systems to simplify administration and expand accessibility, particularly in remote or resource-limited areas. These technological advancements are transforming the anthrax vaccine landscape, addressing unmet needs, and driving market growth.

How Are Regional Dynamics Influencing the Anthrax Vaccine Market?

Regional variations in anthrax prevalence, public health infrastructure, and government policies have a significant impact on the anthrax vaccine market. North America leads the market, driven by strong governmental support for biodefense programs and substantial investments in research and development. The U.S. Department of Health and Human Services (HHS) has been a major purchaser of anthrax vaccines, maintaining strategic national stockpiles to prepare for potential bioterrorism incidents. Europe follows closely, with robust public health systems and stringent regulations supporting the adoption of anthrax vaccination programs. In contrast, the Asia-Pacific region is emerging as a high-growth market due to its large agricultural base, frequent zoonotic outbreaks, and improving healthcare infrastructure. Countries like China and India are ramping up vaccine production and distribution to address both human and animal health concerns. Africa and Latin America, where anthrax remains endemic in certain regions, are also witnessing increased vaccine adoption, supported by global initiatives to enhance access to immunization in low- and middle-income countries. These regional dynamics reflect the global importance of anthrax vaccines in safeguarding both public health and agricultural economies.

What Is Driving Growth in the Anthrax Vaccine Market?

The growth in the anthrax vaccine market is driven by several factors, including increasing government investments in biodefense, advancements in vaccine technologies, and rising awareness of zoonotic diseases. The development of next-generation vaccines with improved safety profiles, reduced dosing schedules, and innovative delivery methods has significantly expanded their appeal. Rising incidences of anthrax outbreaks in livestock-dense regions have further bolstered demand for vaccines in the agricultural sector, emphasizing the importance of protecting both human and animal populations. Consumer awareness of the risks associated with anthrax exposure, coupled with public health initiatives aimed at improving vaccine coverage, has contributed to increased adoption. Additionally, advancements in manufacturing technologies have enabled scalable production of vaccines, ensuring their availability during emergencies. Regional efforts to strengthen healthcare infrastructure and the global focus on biodefense preparedness have also fueled market growth, positioning anthrax vaccines as a critical component in addressing global health and security challenges.

SCOPE OF STUDY:

The report analyzes the Anthrax Vaccine market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product Type (Cell-Free PA Vaccines, Live Cell Vaccines); Distribution Channel (Retail Pharmacy, Hospital Pharmacy, Other Distribution Channels); Application (Animals Application, Humans Application)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 48 Featured) -

  • Bavarian Nordic
  • Bayer AG
  • Cipla
  • Colorado Serum Company
  • Elusys Therapeutics Inc.
  • Emergent BioSolutions
  • Intervac (PVT) Ltd
  • JOVAC
  • MSD Animal Health
  • Neuland Laboratories Ltd.
  • Pfizer Inc.
  • Porton Biopharma Ltd.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

Show more
Product Code: MCP29172

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • Anthrax Vaccine - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Growing Government Investments in National Biodefense Programs Propel Demand for Anthrax Vaccines
    • Rising Bioterrorism Threats Strengthen Business Case for Large-Scale Anthrax Vaccine Stockpiling
    • Expanding Use of Anthrax Vaccines in Military Personnel and First Responders Drives Market Growth
    • Advancements in Recombinant and Adjuvanted Anthrax Vaccines Enhance Immunogenicity and Long-Term Protection
    • Increased R&D Funding in Biopharmaceuticals Strengthens Pipeline for Innovative Anthrax Vaccine Formulations
    • Growing Focus on Global Health Security and Bio-Preparedness Generates Sustained Demand for Anthrax Immunization Solutions
    • Surging Investments in mRNA and DNA Vaccine Platforms Propel Development of Next-Generation Anthrax Vaccines
    • Increasing Awareness of Zoonotic Disease Transmission Expands Addressable Market for Veterinary Anthrax Vaccines
    • Expansion of Cold Chain and Vaccine Logistics Enhances Global Access to Anthrax Immunization Programs
    • Challenges Related to Vaccine Hesitancy and Public Perception Impact Market Penetration of Anthrax Vaccines
    • Rising Adoption of Combination Vaccines Strengthens Market Potential for Multi-Pathogen Anthrax Immunization Solutions
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Anthrax Vaccine Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Anthrax Vaccine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Anthrax Vaccine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Anthrax Vaccine by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Cell-Free PA Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Cell-Free PA Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Cell-Free PA Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Live Cell Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Live Cell Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Live Cell Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Retail Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Retail Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Retail Pharmacy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Hospital Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Hospital Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Hospital Pharmacy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Other Distribution Channels by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Other Distribution Channels by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Other Distribution Channels by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Animals Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Animals Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Animals Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Humans Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Humans Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for Humans Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Anthrax Vaccine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 26: USA Recent Past, Current & Future Analysis for Anthrax Vaccine by Product Type - Cell-Free PA Vaccines and Live Cell Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 27: USA Historic Review for Anthrax Vaccine by Product Type - Cell-Free PA Vaccines and Live Cell Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 28: USA 15-Year Perspective for Anthrax Vaccine by Product Type - Percentage Breakdown of Value Sales for Cell-Free PA Vaccines and Live Cell Vaccines for the Years 2015, 2025 & 2030
    • TABLE 29: USA Recent Past, Current & Future Analysis for Anthrax Vaccine by Distribution Channel - Retail Pharmacy, Hospital Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 30: USA Historic Review for Anthrax Vaccine by Distribution Channel - Retail Pharmacy, Hospital Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 31: USA 15-Year Perspective for Anthrax Vaccine by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacy, Hospital Pharmacy and Other Distribution Channels for the Years 2015, 2025 & 2030
    • TABLE 32: USA Recent Past, Current & Future Analysis for Anthrax Vaccine by Application - Animals Application and Humans Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: USA Historic Review for Anthrax Vaccine by Application - Animals Application and Humans Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 34: USA 15-Year Perspective for Anthrax Vaccine by Application - Percentage Breakdown of Value Sales for Animals Application and Humans Application for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 35: Canada Recent Past, Current & Future Analysis for Anthrax Vaccine by Product Type - Cell-Free PA Vaccines and Live Cell Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Canada Historic Review for Anthrax Vaccine by Product Type - Cell-Free PA Vaccines and Live Cell Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 37: Canada 15-Year Perspective for Anthrax Vaccine by Product Type - Percentage Breakdown of Value Sales for Cell-Free PA Vaccines and Live Cell Vaccines for the Years 2015, 2025 & 2030
    • TABLE 38: Canada Recent Past, Current & Future Analysis for Anthrax Vaccine by Distribution Channel - Retail Pharmacy, Hospital Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Canada Historic Review for Anthrax Vaccine by Distribution Channel - Retail Pharmacy, Hospital Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 40: Canada 15-Year Perspective for Anthrax Vaccine by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacy, Hospital Pharmacy and Other Distribution Channels for the Years 2015, 2025 & 2030
    • TABLE 41: Canada Recent Past, Current & Future Analysis for Anthrax Vaccine by Application - Animals Application and Humans Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Canada Historic Review for Anthrax Vaccine by Application - Animals Application and Humans Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 43: Canada 15-Year Perspective for Anthrax Vaccine by Application - Percentage Breakdown of Value Sales for Animals Application and Humans Application for the Years 2015, 2025 & 2030
  • JAPAN
    • Anthrax Vaccine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 44: Japan Recent Past, Current & Future Analysis for Anthrax Vaccine by Product Type - Cell-Free PA Vaccines and Live Cell Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Japan Historic Review for Anthrax Vaccine by Product Type - Cell-Free PA Vaccines and Live Cell Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 46: Japan 15-Year Perspective for Anthrax Vaccine by Product Type - Percentage Breakdown of Value Sales for Cell-Free PA Vaccines and Live Cell Vaccines for the Years 2015, 2025 & 2030
    • TABLE 47: Japan Recent Past, Current & Future Analysis for Anthrax Vaccine by Distribution Channel - Retail Pharmacy, Hospital Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Japan Historic Review for Anthrax Vaccine by Distribution Channel - Retail Pharmacy, Hospital Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 49: Japan 15-Year Perspective for Anthrax Vaccine by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacy, Hospital Pharmacy and Other Distribution Channels for the Years 2015, 2025 & 2030
    • TABLE 50: Japan Recent Past, Current & Future Analysis for Anthrax Vaccine by Application - Animals Application and Humans Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Japan Historic Review for Anthrax Vaccine by Application - Animals Application and Humans Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 52: Japan 15-Year Perspective for Anthrax Vaccine by Application - Percentage Breakdown of Value Sales for Animals Application and Humans Application for the Years 2015, 2025 & 2030
  • CHINA
    • Anthrax Vaccine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 53: China Recent Past, Current & Future Analysis for Anthrax Vaccine by Product Type - Cell-Free PA Vaccines and Live Cell Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: China Historic Review for Anthrax Vaccine by Product Type - Cell-Free PA Vaccines and Live Cell Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 55: China 15-Year Perspective for Anthrax Vaccine by Product Type - Percentage Breakdown of Value Sales for Cell-Free PA Vaccines and Live Cell Vaccines for the Years 2015, 2025 & 2030
    • TABLE 56: China Recent Past, Current & Future Analysis for Anthrax Vaccine by Distribution Channel - Retail Pharmacy, Hospital Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: China Historic Review for Anthrax Vaccine by Distribution Channel - Retail Pharmacy, Hospital Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 58: China 15-Year Perspective for Anthrax Vaccine by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacy, Hospital Pharmacy and Other Distribution Channels for the Years 2015, 2025 & 2030
    • TABLE 59: China Recent Past, Current & Future Analysis for Anthrax Vaccine by Application - Animals Application and Humans Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: China Historic Review for Anthrax Vaccine by Application - Animals Application and Humans Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 61: China 15-Year Perspective for Anthrax Vaccine by Application - Percentage Breakdown of Value Sales for Animals Application and Humans Application for the Years 2015, 2025 & 2030
  • EUROPE
    • Anthrax Vaccine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 62: Europe Recent Past, Current & Future Analysis for Anthrax Vaccine by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 63: Europe Historic Review for Anthrax Vaccine by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 64: Europe 15-Year Perspective for Anthrax Vaccine by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 65: Europe Recent Past, Current & Future Analysis for Anthrax Vaccine by Product Type - Cell-Free PA Vaccines and Live Cell Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Europe Historic Review for Anthrax Vaccine by Product Type - Cell-Free PA Vaccines and Live Cell Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 67: Europe 15-Year Perspective for Anthrax Vaccine by Product Type - Percentage Breakdown of Value Sales for Cell-Free PA Vaccines and Live Cell Vaccines for the Years 2015, 2025 & 2030
    • TABLE 68: Europe Recent Past, Current & Future Analysis for Anthrax Vaccine by Distribution Channel - Retail Pharmacy, Hospital Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Europe Historic Review for Anthrax Vaccine by Distribution Channel - Retail Pharmacy, Hospital Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 70: Europe 15-Year Perspective for Anthrax Vaccine by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacy, Hospital Pharmacy and Other Distribution Channels for the Years 2015, 2025 & 2030
    • TABLE 71: Europe Recent Past, Current & Future Analysis for Anthrax Vaccine by Application - Animals Application and Humans Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Europe Historic Review for Anthrax Vaccine by Application - Animals Application and Humans Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 73: Europe 15-Year Perspective for Anthrax Vaccine by Application - Percentage Breakdown of Value Sales for Animals Application and Humans Application for the Years 2015, 2025 & 2030
  • FRANCE
    • Anthrax Vaccine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 74: France Recent Past, Current & Future Analysis for Anthrax Vaccine by Product Type - Cell-Free PA Vaccines and Live Cell Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: France Historic Review for Anthrax Vaccine by Product Type - Cell-Free PA Vaccines and Live Cell Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 76: France 15-Year Perspective for Anthrax Vaccine by Product Type - Percentage Breakdown of Value Sales for Cell-Free PA Vaccines and Live Cell Vaccines for the Years 2015, 2025 & 2030
    • TABLE 77: France Recent Past, Current & Future Analysis for Anthrax Vaccine by Distribution Channel - Retail Pharmacy, Hospital Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: France Historic Review for Anthrax Vaccine by Distribution Channel - Retail Pharmacy, Hospital Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 79: France 15-Year Perspective for Anthrax Vaccine by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacy, Hospital Pharmacy and Other Distribution Channels for the Years 2015, 2025 & 2030
    • TABLE 80: France Recent Past, Current & Future Analysis for Anthrax Vaccine by Application - Animals Application and Humans Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: France Historic Review for Anthrax Vaccine by Application - Animals Application and Humans Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 82: France 15-Year Perspective for Anthrax Vaccine by Application - Percentage Breakdown of Value Sales for Animals Application and Humans Application for the Years 2015, 2025 & 2030
  • GERMANY
    • Anthrax Vaccine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 83: Germany Recent Past, Current & Future Analysis for Anthrax Vaccine by Product Type - Cell-Free PA Vaccines and Live Cell Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Germany Historic Review for Anthrax Vaccine by Product Type - Cell-Free PA Vaccines and Live Cell Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 85: Germany 15-Year Perspective for Anthrax Vaccine by Product Type - Percentage Breakdown of Value Sales for Cell-Free PA Vaccines and Live Cell Vaccines for the Years 2015, 2025 & 2030
    • TABLE 86: Germany Recent Past, Current & Future Analysis for Anthrax Vaccine by Distribution Channel - Retail Pharmacy, Hospital Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Germany Historic Review for Anthrax Vaccine by Distribution Channel - Retail Pharmacy, Hospital Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 88: Germany 15-Year Perspective for Anthrax Vaccine by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacy, Hospital Pharmacy and Other Distribution Channels for the Years 2015, 2025 & 2030
    • TABLE 89: Germany Recent Past, Current & Future Analysis for Anthrax Vaccine by Application - Animals Application and Humans Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Germany Historic Review for Anthrax Vaccine by Application - Animals Application and Humans Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 91: Germany 15-Year Perspective for Anthrax Vaccine by Application - Percentage Breakdown of Value Sales for Animals Application and Humans Application for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 92: Italy Recent Past, Current & Future Analysis for Anthrax Vaccine by Product Type - Cell-Free PA Vaccines and Live Cell Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Italy Historic Review for Anthrax Vaccine by Product Type - Cell-Free PA Vaccines and Live Cell Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 94: Italy 15-Year Perspective for Anthrax Vaccine by Product Type - Percentage Breakdown of Value Sales for Cell-Free PA Vaccines and Live Cell Vaccines for the Years 2015, 2025 & 2030
    • TABLE 95: Italy Recent Past, Current & Future Analysis for Anthrax Vaccine by Distribution Channel - Retail Pharmacy, Hospital Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Italy Historic Review for Anthrax Vaccine by Distribution Channel - Retail Pharmacy, Hospital Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 97: Italy 15-Year Perspective for Anthrax Vaccine by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacy, Hospital Pharmacy and Other Distribution Channels for the Years 2015, 2025 & 2030
    • TABLE 98: Italy Recent Past, Current & Future Analysis for Anthrax Vaccine by Application - Animals Application and Humans Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Italy Historic Review for Anthrax Vaccine by Application - Animals Application and Humans Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 100: Italy 15-Year Perspective for Anthrax Vaccine by Application - Percentage Breakdown of Value Sales for Animals Application and Humans Application for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Anthrax Vaccine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 101: UK Recent Past, Current & Future Analysis for Anthrax Vaccine by Product Type - Cell-Free PA Vaccines and Live Cell Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: UK Historic Review for Anthrax Vaccine by Product Type - Cell-Free PA Vaccines and Live Cell Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 103: UK 15-Year Perspective for Anthrax Vaccine by Product Type - Percentage Breakdown of Value Sales for Cell-Free PA Vaccines and Live Cell Vaccines for the Years 2015, 2025 & 2030
    • TABLE 104: UK Recent Past, Current & Future Analysis for Anthrax Vaccine by Distribution Channel - Retail Pharmacy, Hospital Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: UK Historic Review for Anthrax Vaccine by Distribution Channel - Retail Pharmacy, Hospital Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 106: UK 15-Year Perspective for Anthrax Vaccine by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacy, Hospital Pharmacy and Other Distribution Channels for the Years 2015, 2025 & 2030
    • TABLE 107: UK Recent Past, Current & Future Analysis for Anthrax Vaccine by Application - Animals Application and Humans Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: UK Historic Review for Anthrax Vaccine by Application - Animals Application and Humans Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 109: UK 15-Year Perspective for Anthrax Vaccine by Application - Percentage Breakdown of Value Sales for Animals Application and Humans Application for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 110: Spain Recent Past, Current & Future Analysis for Anthrax Vaccine by Product Type - Cell-Free PA Vaccines and Live Cell Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Spain Historic Review for Anthrax Vaccine by Product Type - Cell-Free PA Vaccines and Live Cell Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 112: Spain 15-Year Perspective for Anthrax Vaccine by Product Type - Percentage Breakdown of Value Sales for Cell-Free PA Vaccines and Live Cell Vaccines for the Years 2015, 2025 & 2030
    • TABLE 113: Spain Recent Past, Current & Future Analysis for Anthrax Vaccine by Distribution Channel - Retail Pharmacy, Hospital Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Spain Historic Review for Anthrax Vaccine by Distribution Channel - Retail Pharmacy, Hospital Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 115: Spain 15-Year Perspective for Anthrax Vaccine by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacy, Hospital Pharmacy and Other Distribution Channels for the Years 2015, 2025 & 2030
    • TABLE 116: Spain Recent Past, Current & Future Analysis for Anthrax Vaccine by Application - Animals Application and Humans Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Spain Historic Review for Anthrax Vaccine by Application - Animals Application and Humans Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 118: Spain 15-Year Perspective for Anthrax Vaccine by Application - Percentage Breakdown of Value Sales for Animals Application and Humans Application for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 119: Russia Recent Past, Current & Future Analysis for Anthrax Vaccine by Product Type - Cell-Free PA Vaccines and Live Cell Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: Russia Historic Review for Anthrax Vaccine by Product Type - Cell-Free PA Vaccines and Live Cell Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 121: Russia 15-Year Perspective for Anthrax Vaccine by Product Type - Percentage Breakdown of Value Sales for Cell-Free PA Vaccines and Live Cell Vaccines for the Years 2015, 2025 & 2030
    • TABLE 122: Russia Recent Past, Current & Future Analysis for Anthrax Vaccine by Distribution Channel - Retail Pharmacy, Hospital Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Russia Historic Review for Anthrax Vaccine by Distribution Channel - Retail Pharmacy, Hospital Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 124: Russia 15-Year Perspective for Anthrax Vaccine by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacy, Hospital Pharmacy and Other Distribution Channels for the Years 2015, 2025 & 2030
    • TABLE 125: Russia Recent Past, Current & Future Analysis for Anthrax Vaccine by Application - Animals Application and Humans Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Russia Historic Review for Anthrax Vaccine by Application - Animals Application and Humans Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 127: Russia 15-Year Perspective for Anthrax Vaccine by Application - Percentage Breakdown of Value Sales for Animals Application and Humans Application for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 128: Rest of Europe Recent Past, Current & Future Analysis for Anthrax Vaccine by Product Type - Cell-Free PA Vaccines and Live Cell Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Rest of Europe Historic Review for Anthrax Vaccine by Product Type - Cell-Free PA Vaccines and Live Cell Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 130: Rest of Europe 15-Year Perspective for Anthrax Vaccine by Product Type - Percentage Breakdown of Value Sales for Cell-Free PA Vaccines and Live Cell Vaccines for the Years 2015, 2025 & 2030
    • TABLE 131: Rest of Europe Recent Past, Current & Future Analysis for Anthrax Vaccine by Distribution Channel - Retail Pharmacy, Hospital Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Rest of Europe Historic Review for Anthrax Vaccine by Distribution Channel - Retail Pharmacy, Hospital Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 133: Rest of Europe 15-Year Perspective for Anthrax Vaccine by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacy, Hospital Pharmacy and Other Distribution Channels for the Years 2015, 2025 & 2030
    • TABLE 134: Rest of Europe Recent Past, Current & Future Analysis for Anthrax Vaccine by Application - Animals Application and Humans Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Rest of Europe Historic Review for Anthrax Vaccine by Application - Animals Application and Humans Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 136: Rest of Europe 15-Year Perspective for Anthrax Vaccine by Application - Percentage Breakdown of Value Sales for Animals Application and Humans Application for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Anthrax Vaccine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 137: Asia-Pacific Recent Past, Current & Future Analysis for Anthrax Vaccine by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 138: Asia-Pacific Historic Review for Anthrax Vaccine by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 139: Asia-Pacific 15-Year Perspective for Anthrax Vaccine by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 140: Asia-Pacific Recent Past, Current & Future Analysis for Anthrax Vaccine by Product Type - Cell-Free PA Vaccines and Live Cell Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Asia-Pacific Historic Review for Anthrax Vaccine by Product Type - Cell-Free PA Vaccines and Live Cell Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 142: Asia-Pacific 15-Year Perspective for Anthrax Vaccine by Product Type - Percentage Breakdown of Value Sales for Cell-Free PA Vaccines and Live Cell Vaccines for the Years 2015, 2025 & 2030
    • TABLE 143: Asia-Pacific Recent Past, Current & Future Analysis for Anthrax Vaccine by Distribution Channel - Retail Pharmacy, Hospital Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Asia-Pacific Historic Review for Anthrax Vaccine by Distribution Channel - Retail Pharmacy, Hospital Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 145: Asia-Pacific 15-Year Perspective for Anthrax Vaccine by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacy, Hospital Pharmacy and Other Distribution Channels for the Years 2015, 2025 & 2030
    • TABLE 146: Asia-Pacific Recent Past, Current & Future Analysis for Anthrax Vaccine by Application - Animals Application and Humans Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Asia-Pacific Historic Review for Anthrax Vaccine by Application - Animals Application and Humans Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 148: Asia-Pacific 15-Year Perspective for Anthrax Vaccine by Application - Percentage Breakdown of Value Sales for Animals Application and Humans Application for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Anthrax Vaccine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 149: Australia Recent Past, Current & Future Analysis for Anthrax Vaccine by Product Type - Cell-Free PA Vaccines and Live Cell Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Australia Historic Review for Anthrax Vaccine by Product Type - Cell-Free PA Vaccines and Live Cell Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 151: Australia 15-Year Perspective for Anthrax Vaccine by Product Type - Percentage Breakdown of Value Sales for Cell-Free PA Vaccines and Live Cell Vaccines for the Years 2015, 2025 & 2030
    • TABLE 152: Australia Recent Past, Current & Future Analysis for Anthrax Vaccine by Distribution Channel - Retail Pharmacy, Hospital Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Australia Historic Review for Anthrax Vaccine by Distribution Channel - Retail Pharmacy, Hospital Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 154: Australia 15-Year Perspective for Anthrax Vaccine by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacy, Hospital Pharmacy and Other Distribution Channels for the Years 2015, 2025 & 2030
    • TABLE 155: Australia Recent Past, Current & Future Analysis for Anthrax Vaccine by Application - Animals Application and Humans Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Australia Historic Review for Anthrax Vaccine by Application - Animals Application and Humans Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 157: Australia 15-Year Perspective for Anthrax Vaccine by Application - Percentage Breakdown of Value Sales for Animals Application and Humans Application for the Years 2015, 2025 & 2030
  • INDIA
    • Anthrax Vaccine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 158: India Recent Past, Current & Future Analysis for Anthrax Vaccine by Product Type - Cell-Free PA Vaccines and Live Cell Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: India Historic Review for Anthrax Vaccine by Product Type - Cell-Free PA Vaccines and Live Cell Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 160: India 15-Year Perspective for Anthrax Vaccine by Product Type - Percentage Breakdown of Value Sales for Cell-Free PA Vaccines and Live Cell Vaccines for the Years 2015, 2025 & 2030
    • TABLE 161: India Recent Past, Current & Future Analysis for Anthrax Vaccine by Distribution Channel - Retail Pharmacy, Hospital Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: India Historic Review for Anthrax Vaccine by Distribution Channel - Retail Pharmacy, Hospital Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 163: India 15-Year Perspective for Anthrax Vaccine by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacy, Hospital Pharmacy and Other Distribution Channels for the Years 2015, 2025 & 2030
    • TABLE 164: India Recent Past, Current & Future Analysis for Anthrax Vaccine by Application - Animals Application and Humans Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: India Historic Review for Anthrax Vaccine by Application - Animals Application and Humans Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 166: India 15-Year Perspective for Anthrax Vaccine by Application - Percentage Breakdown of Value Sales for Animals Application and Humans Application for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 167: South Korea Recent Past, Current & Future Analysis for Anthrax Vaccine by Product Type - Cell-Free PA Vaccines and Live Cell Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 168: South Korea Historic Review for Anthrax Vaccine by Product Type - Cell-Free PA Vaccines and Live Cell Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 169: South Korea 15-Year Perspective for Anthrax Vaccine by Product Type - Percentage Breakdown of Value Sales for Cell-Free PA Vaccines and Live Cell Vaccines for the Years 2015, 2025 & 2030
    • TABLE 170: South Korea Recent Past, Current & Future Analysis for Anthrax Vaccine by Distribution Channel - Retail Pharmacy, Hospital Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 171: South Korea Historic Review for Anthrax Vaccine by Distribution Channel - Retail Pharmacy, Hospital Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 172: South Korea 15-Year Perspective for Anthrax Vaccine by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacy, Hospital Pharmacy and Other Distribution Channels for the Years 2015, 2025 & 2030
    • TABLE 173: South Korea Recent Past, Current & Future Analysis for Anthrax Vaccine by Application - Animals Application and Humans Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: South Korea Historic Review for Anthrax Vaccine by Application - Animals Application and Humans Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 175: South Korea 15-Year Perspective for Anthrax Vaccine by Application - Percentage Breakdown of Value Sales for Animals Application and Humans Application for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 176: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Anthrax Vaccine by Product Type - Cell-Free PA Vaccines and Live Cell Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Rest of Asia-Pacific Historic Review for Anthrax Vaccine by Product Type - Cell-Free PA Vaccines and Live Cell Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 178: Rest of Asia-Pacific 15-Year Perspective for Anthrax Vaccine by Product Type - Percentage Breakdown of Value Sales for Cell-Free PA Vaccines and Live Cell Vaccines for the Years 2015, 2025 & 2030
    • TABLE 179: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Anthrax Vaccine by Distribution Channel - Retail Pharmacy, Hospital Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Rest of Asia-Pacific Historic Review for Anthrax Vaccine by Distribution Channel - Retail Pharmacy, Hospital Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 181: Rest of Asia-Pacific 15-Year Perspective for Anthrax Vaccine by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacy, Hospital Pharmacy and Other Distribution Channels for the Years 2015, 2025 & 2030
    • TABLE 182: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Anthrax Vaccine by Application - Animals Application and Humans Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Rest of Asia-Pacific Historic Review for Anthrax Vaccine by Application - Animals Application and Humans Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 184: Rest of Asia-Pacific 15-Year Perspective for Anthrax Vaccine by Application - Percentage Breakdown of Value Sales for Animals Application and Humans Application for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Anthrax Vaccine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 185: Latin America Recent Past, Current & Future Analysis for Anthrax Vaccine by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 186: Latin America Historic Review for Anthrax Vaccine by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 187: Latin America 15-Year Perspective for Anthrax Vaccine by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 188: Latin America Recent Past, Current & Future Analysis for Anthrax Vaccine by Product Type - Cell-Free PA Vaccines and Live Cell Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Latin America Historic Review for Anthrax Vaccine by Product Type - Cell-Free PA Vaccines and Live Cell Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 190: Latin America 15-Year Perspective for Anthrax Vaccine by Product Type - Percentage Breakdown of Value Sales for Cell-Free PA Vaccines and Live Cell Vaccines for the Years 2015, 2025 & 2030
    • TABLE 191: Latin America Recent Past, Current & Future Analysis for Anthrax Vaccine by Distribution Channel - Retail Pharmacy, Hospital Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Latin America Historic Review for Anthrax Vaccine by Distribution Channel - Retail Pharmacy, Hospital Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 193: Latin America 15-Year Perspective for Anthrax Vaccine by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacy, Hospital Pharmacy and Other Distribution Channels for the Years 2015, 2025 & 2030
    • TABLE 194: Latin America Recent Past, Current & Future Analysis for Anthrax Vaccine by Application - Animals Application and Humans Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Latin America Historic Review for Anthrax Vaccine by Application - Animals Application and Humans Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 196: Latin America 15-Year Perspective for Anthrax Vaccine by Application - Percentage Breakdown of Value Sales for Animals Application and Humans Application for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 197: Argentina Recent Past, Current & Future Analysis for Anthrax Vaccine by Product Type - Cell-Free PA Vaccines and Live Cell Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Argentina Historic Review for Anthrax Vaccine by Product Type - Cell-Free PA Vaccines and Live Cell Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 199: Argentina 15-Year Perspective for Anthrax Vaccine by Product Type - Percentage Breakdown of Value Sales for Cell-Free PA Vaccines and Live Cell Vaccines for the Years 2015, 2025 & 2030
    • TABLE 200: Argentina Recent Past, Current & Future Analysis for Anthrax Vaccine by Distribution Channel - Retail Pharmacy, Hospital Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Argentina Historic Review for Anthrax Vaccine by Distribution Channel - Retail Pharmacy, Hospital Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 202: Argentina 15-Year Perspective for Anthrax Vaccine by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacy, Hospital Pharmacy and Other Distribution Channels for the Years 2015, 2025 & 2030
    • TABLE 203: Argentina Recent Past, Current & Future Analysis for Anthrax Vaccine by Application - Animals Application and Humans Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Argentina Historic Review for Anthrax Vaccine by Application - Animals Application and Humans Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 205: Argentina 15-Year Perspective for Anthrax Vaccine by Application - Percentage Breakdown of Value Sales for Animals Application and Humans Application for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 206: Brazil Recent Past, Current & Future Analysis for Anthrax Vaccine by Product Type - Cell-Free PA Vaccines and Live Cell Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Brazil Historic Review for Anthrax Vaccine by Product Type - Cell-Free PA Vaccines and Live Cell Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 208: Brazil 15-Year Perspective for Anthrax Vaccine by Product Type - Percentage Breakdown of Value Sales for Cell-Free PA Vaccines and Live Cell Vaccines for the Years 2015, 2025 & 2030
    • TABLE 209: Brazil Recent Past, Current & Future Analysis for Anthrax Vaccine by Distribution Channel - Retail Pharmacy, Hospital Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Brazil Historic Review for Anthrax Vaccine by Distribution Channel - Retail Pharmacy, Hospital Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 211: Brazil 15-Year Perspective for Anthrax Vaccine by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacy, Hospital Pharmacy and Other Distribution Channels for the Years 2015, 2025 & 2030
    • TABLE 212: Brazil Recent Past, Current & Future Analysis for Anthrax Vaccine by Application - Animals Application and Humans Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Brazil Historic Review for Anthrax Vaccine by Application - Animals Application and Humans Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 214: Brazil 15-Year Perspective for Anthrax Vaccine by Application - Percentage Breakdown of Value Sales for Animals Application and Humans Application for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 215: Mexico Recent Past, Current & Future Analysis for Anthrax Vaccine by Product Type - Cell-Free PA Vaccines and Live Cell Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 216: Mexico Historic Review for Anthrax Vaccine by Product Type - Cell-Free PA Vaccines and Live Cell Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 217: Mexico 15-Year Perspective for Anthrax Vaccine by Product Type - Percentage Breakdown of Value Sales for Cell-Free PA Vaccines and Live Cell Vaccines for the Years 2015, 2025 & 2030
    • TABLE 218: Mexico Recent Past, Current & Future Analysis for Anthrax Vaccine by Distribution Channel - Retail Pharmacy, Hospital Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 219: Mexico Historic Review for Anthrax Vaccine by Distribution Channel - Retail Pharmacy, Hospital Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 220: Mexico 15-Year Perspective for Anthrax Vaccine by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacy, Hospital Pharmacy and Other Distribution Channels for the Years 2015, 2025 & 2030
    • TABLE 221: Mexico Recent Past, Current & Future Analysis for Anthrax Vaccine by Application - Animals Application and Humans Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 222: Mexico Historic Review for Anthrax Vaccine by Application - Animals Application and Humans Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 223: Mexico 15-Year Perspective for Anthrax Vaccine by Application - Percentage Breakdown of Value Sales for Animals Application and Humans Application for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 224: Rest of Latin America Recent Past, Current & Future Analysis for Anthrax Vaccine by Product Type - Cell-Free PA Vaccines and Live Cell Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 225: Rest of Latin America Historic Review for Anthrax Vaccine by Product Type - Cell-Free PA Vaccines and Live Cell Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 226: Rest of Latin America 15-Year Perspective for Anthrax Vaccine by Product Type - Percentage Breakdown of Value Sales for Cell-Free PA Vaccines and Live Cell Vaccines for the Years 2015, 2025 & 2030
    • TABLE 227: Rest of Latin America Recent Past, Current & Future Analysis for Anthrax Vaccine by Distribution Channel - Retail Pharmacy, Hospital Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 228: Rest of Latin America Historic Review for Anthrax Vaccine by Distribution Channel - Retail Pharmacy, Hospital Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 229: Rest of Latin America 15-Year Perspective for Anthrax Vaccine by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacy, Hospital Pharmacy and Other Distribution Channels for the Years 2015, 2025 & 2030
    • TABLE 230: Rest of Latin America Recent Past, Current & Future Analysis for Anthrax Vaccine by Application - Animals Application and Humans Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 231: Rest of Latin America Historic Review for Anthrax Vaccine by Application - Animals Application and Humans Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 232: Rest of Latin America 15-Year Perspective for Anthrax Vaccine by Application - Percentage Breakdown of Value Sales for Animals Application and Humans Application for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Anthrax Vaccine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 233: Middle East Recent Past, Current & Future Analysis for Anthrax Vaccine by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 234: Middle East Historic Review for Anthrax Vaccine by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 235: Middle East 15-Year Perspective for Anthrax Vaccine by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 236: Middle East Recent Past, Current & Future Analysis for Anthrax Vaccine by Product Type - Cell-Free PA Vaccines and Live Cell Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 237: Middle East Historic Review for Anthrax Vaccine by Product Type - Cell-Free PA Vaccines and Live Cell Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 238: Middle East 15-Year Perspective for Anthrax Vaccine by Product Type - Percentage Breakdown of Value Sales for Cell-Free PA Vaccines and Live Cell Vaccines for the Years 2015, 2025 & 2030
    • TABLE 239: Middle East Recent Past, Current & Future Analysis for Anthrax Vaccine by Distribution Channel - Retail Pharmacy, Hospital Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 240: Middle East Historic Review for Anthrax Vaccine by Distribution Channel - Retail Pharmacy, Hospital Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 241: Middle East 15-Year Perspective for Anthrax Vaccine by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacy, Hospital Pharmacy and Other Distribution Channels for the Years 2015, 2025 & 2030
    • TABLE 242: Middle East Recent Past, Current & Future Analysis for Anthrax Vaccine by Application - Animals Application and Humans Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 243: Middle East Historic Review for Anthrax Vaccine by Application - Animals Application and Humans Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 244: Middle East 15-Year Perspective for Anthrax Vaccine by Application - Percentage Breakdown of Value Sales for Animals Application and Humans Application for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 245: Iran Recent Past, Current & Future Analysis for Anthrax Vaccine by Product Type - Cell-Free PA Vaccines and Live Cell Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 246: Iran Historic Review for Anthrax Vaccine by Product Type - Cell-Free PA Vaccines and Live Cell Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 247: Iran 15-Year Perspective for Anthrax Vaccine by Product Type - Percentage Breakdown of Value Sales for Cell-Free PA Vaccines and Live Cell Vaccines for the Years 2015, 2025 & 2030
    • TABLE 248: Iran Recent Past, Current & Future Analysis for Anthrax Vaccine by Distribution Channel - Retail Pharmacy, Hospital Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 249: Iran Historic Review for Anthrax Vaccine by Distribution Channel - Retail Pharmacy, Hospital Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 250: Iran 15-Year Perspective for Anthrax Vaccine by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacy, Hospital Pharmacy and Other Distribution Channels for the Years 2015, 2025 & 2030
    • TABLE 251: Iran Recent Past, Current & Future Analysis for Anthrax Vaccine by Application - Animals Application and Humans Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 252: Iran Historic Review for Anthrax Vaccine by Application - Animals Application and Humans Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 253: Iran 15-Year Perspective for Anthrax Vaccine by Application - Percentage Breakdown of Value Sales for Animals Application and Humans Application for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 254: Israel Recent Past, Current & Future Analysis for Anthrax Vaccine by Product Type - Cell-Free PA Vaccines and Live Cell Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 255: Israel Historic Review for Anthrax Vaccine by Product Type - Cell-Free PA Vaccines and Live Cell Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 256: Israel 15-Year Perspective for Anthrax Vaccine by Product Type - Percentage Breakdown of Value Sales for Cell-Free PA Vaccines and Live Cell Vaccines for the Years 2015, 2025 & 2030
    • TABLE 257: Israel Recent Past, Current & Future Analysis for Anthrax Vaccine by Distribution Channel - Retail Pharmacy, Hospital Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 258: Israel Historic Review for Anthrax Vaccine by Distribution Channel - Retail Pharmacy, Hospital Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 259: Israel 15-Year Perspective for Anthrax Vaccine by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacy, Hospital Pharmacy and Other Distribution Channels for the Years 2015, 2025 & 2030
    • TABLE 260: Israel Recent Past, Current & Future Analysis for Anthrax Vaccine by Application - Animals Application and Humans Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 261: Israel Historic Review for Anthrax Vaccine by Application - Animals Application and Humans Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 262: Israel 15-Year Perspective for Anthrax Vaccine by Application - Percentage Breakdown of Value Sales for Animals Application and Humans Application for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 263: Saudi Arabia Recent Past, Current & Future Analysis for Anthrax Vaccine by Product Type - Cell-Free PA Vaccines and Live Cell Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 264: Saudi Arabia Historic Review for Anthrax Vaccine by Product Type - Cell-Free PA Vaccines and Live Cell Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 265: Saudi Arabia 15-Year Perspective for Anthrax Vaccine by Product Type - Percentage Breakdown of Value Sales for Cell-Free PA Vaccines and Live Cell Vaccines for the Years 2015, 2025 & 2030
    • TABLE 266: Saudi Arabia Recent Past, Current & Future Analysis for Anthrax Vaccine by Distribution Channel - Retail Pharmacy, Hospital Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 267: Saudi Arabia Historic Review for Anthrax Vaccine by Distribution Channel - Retail Pharmacy, Hospital Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 268: Saudi Arabia 15-Year Perspective for Anthrax Vaccine by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacy, Hospital Pharmacy and Other Distribution Channels for the Years 2015, 2025 & 2030
    • TABLE 269: Saudi Arabia Recent Past, Current & Future Analysis for Anthrax Vaccine by Application - Animals Application and Humans Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 270: Saudi Arabia Historic Review for Anthrax Vaccine by Application - Animals Application and Humans Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 271: Saudi Arabia 15-Year Perspective for Anthrax Vaccine by Application - Percentage Breakdown of Value Sales for Animals Application and Humans Application for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 272: UAE Recent Past, Current & Future Analysis for Anthrax Vaccine by Product Type - Cell-Free PA Vaccines and Live Cell Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 273: UAE Historic Review for Anthrax Vaccine by Product Type - Cell-Free PA Vaccines and Live Cell Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 274: UAE 15-Year Perspective for Anthrax Vaccine by Product Type - Percentage Breakdown of Value Sales for Cell-Free PA Vaccines and Live Cell Vaccines for the Years 2015, 2025 & 2030
    • TABLE 275: UAE Recent Past, Current & Future Analysis for Anthrax Vaccine by Distribution Channel - Retail Pharmacy, Hospital Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 276: UAE Historic Review for Anthrax Vaccine by Distribution Channel - Retail Pharmacy, Hospital Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 277: UAE 15-Year Perspective for Anthrax Vaccine by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacy, Hospital Pharmacy and Other Distribution Channels for the Years 2015, 2025 & 2030
    • TABLE 278: UAE Recent Past, Current & Future Analysis for Anthrax Vaccine by Application - Animals Application and Humans Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 279: UAE Historic Review for Anthrax Vaccine by Application - Animals Application and Humans Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 280: UAE 15-Year Perspective for Anthrax Vaccine by Application - Percentage Breakdown of Value Sales for Animals Application and Humans Application for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 281: Rest of Middle East Recent Past, Current & Future Analysis for Anthrax Vaccine by Product Type - Cell-Free PA Vaccines and Live Cell Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 282: Rest of Middle East Historic Review for Anthrax Vaccine by Product Type - Cell-Free PA Vaccines and Live Cell Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 283: Rest of Middle East 15-Year Perspective for Anthrax Vaccine by Product Type - Percentage Breakdown of Value Sales for Cell-Free PA Vaccines and Live Cell Vaccines for the Years 2015, 2025 & 2030
    • TABLE 284: Rest of Middle East Recent Past, Current & Future Analysis for Anthrax Vaccine by Distribution Channel - Retail Pharmacy, Hospital Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 285: Rest of Middle East Historic Review for Anthrax Vaccine by Distribution Channel - Retail Pharmacy, Hospital Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 286: Rest of Middle East 15-Year Perspective for Anthrax Vaccine by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacy, Hospital Pharmacy and Other Distribution Channels for the Years 2015, 2025 & 2030
    • TABLE 287: Rest of Middle East Recent Past, Current & Future Analysis for Anthrax Vaccine by Application - Animals Application and Humans Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 288: Rest of Middle East Historic Review for Anthrax Vaccine by Application - Animals Application and Humans Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 289: Rest of Middle East 15-Year Perspective for Anthrax Vaccine by Application - Percentage Breakdown of Value Sales for Animals Application and Humans Application for the Years 2015, 2025 & 2030
  • AFRICA
    • Anthrax Vaccine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 290: Africa Recent Past, Current & Future Analysis for Anthrax Vaccine by Product Type - Cell-Free PA Vaccines and Live Cell Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 291: Africa Historic Review for Anthrax Vaccine by Product Type - Cell-Free PA Vaccines and Live Cell Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 292: Africa 15-Year Perspective for Anthrax Vaccine by Product Type - Percentage Breakdown of Value Sales for Cell-Free PA Vaccines and Live Cell Vaccines for the Years 2015, 2025 & 2030
    • TABLE 293: Africa Recent Past, Current & Future Analysis for Anthrax Vaccine by Distribution Channel - Retail Pharmacy, Hospital Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 294: Africa Historic Review for Anthrax Vaccine by Distribution Channel - Retail Pharmacy, Hospital Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 295: Africa 15-Year Perspective for Anthrax Vaccine by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacy, Hospital Pharmacy and Other Distribution Channels for the Years 2015, 2025 & 2030
    • TABLE 296: Africa Recent Past, Current & Future Analysis for Anthrax Vaccine by Application - Animals Application and Humans Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 297: Africa Historic Review for Anthrax Vaccine by Application - Animals Application and Humans Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 298: Africa 15-Year Perspective for Anthrax Vaccine by Application - Percentage Breakdown of Value Sales for Animals Application and Humans Application for the Years 2015, 2025 & 2030

IV. COMPETITION

Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!